Antilymphocyte Serum: all 156 studies that test it
Page 1 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBTNot yet recruitingNCT07885982Phase 2
- Population PK-guided ATG Dosing for Haploidentical Hematopoietic Stem Cell TransplantationRecruitingNCT07862127Phase 3
- Population PK-guided ATG Dosing in Haplo-HSCTRecruitingNCT07791576Phase 2
- A Study of VABu Conditioning Regimen in Allo-HSCT for AML PatientsNot yet recruitingNCT07762508Not applicable
- Individualized Application of Anti-Thymocyte Globulin(ATG)in Unrelated Donor Hematopoietic Stem Cell TransplantationRecruitingNCT07648992Phase 4
- Haplo-Cord HSCT for AML/MDSRecruitingNCT07588360Not applicable
- Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATGRecruitingNCT07216391Phase 2
- Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn DiseaseNot yet recruitingNCT06986382Phase 1/2
- Precision Administration of Anti-thymocyte Globulin With or Without VerapamilRecruitingNCT06455319Phase 2
- A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic AnemiaRecruitingNCT05757310Phase 1
- Allogeneic Hematopoietic Stem Cell Transplantation for 4/M NeuroblastomaNot yet recruitingNCT05303727Phase 2
- Stem Cell Transplantation in Crohn's DiseaseRecruitingNCT04224558Phase 1/2
- Autologous Stem Cell Transplantation in Patients With Systemic SclerosisRecruitingNCT03630211Phase 2
- Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell DiseaseRecruitingNCT03121001Phase 2
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 MutationsRecruitingNCT01861106Phase 2
- Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic SyndromeRecruitingNCT01624805Phase 2
- Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.TerminatedNCT05579769Phase 2Results posted
- STOP-T1D Low-Dose (ATG)TerminatedNCT04291703Phase 2Results posted
- Treg Modulation With CD28 and IL-6 Receptor AntagonistsCompletedNCT04066114Phase 1/2Results posted
- Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell TransplantationCompletedNCT03734601Phase 2Results posted
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or DysregulationActive, not recruitingNCT03663933Phase 2Results posted
- Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
- Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)CompletedNCT02918292Phase 2Results posted
- ATG-GCSF in New Onset Type 1 DiabetesCompletedNCT02215200Phase 2Results posted
- Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal DiseaseCompletedNCT02158052Not applicableResults posted
- T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic TransplantTerminatedNCT01621477Phase 2Results posted
- Scleroderma Treatment With Autologous Transplant (STAT) StudyCompletedNCT01413100Phase 2Results posted
- Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATGCompletedNCT01390402Phase 2Results posted
- NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid DiseasesCompletedNCT01370213Phase 2Results posted
- Research Study of ATG and Rituximab in Renal TransplantationTerminatedNCT01318915Early Phase 1Results posted
- A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell DiseaseTerminatedNCT01279616Phase 2Results posted
- Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic AnemiaCompletedNCT01231841Phase 2Results posted
- Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid LeukemiaCompletedNCT01168219Phase 2Results posted
- Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantTerminatedNCT01118013Phase 2Results posted
- Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 2Results posted
- Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cellsTerminatedNCT01050764Phase 1/2Results posted
- Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCsCompletedNCT01033552Phase 1/2Results posted
- Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA TreatmentCompletedNCT00944749Phase 2Results posted
- Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMACCompletedNCT00923364Phase 2Results posted
- Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell LymphomaCompletedNCT00896493Phase 2Results posted
- Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic CancerTerminatedNCT00827099Phase 2Results posted
- Autologous and Allogeneic Transplant for Relapsed LymphomaCompletedNCT00802113Phase 1/2Results posted
- Double Cord Blood Transplant for Patients With Malignant and Non-malignant DisordersTerminatedNCT00801931Phase 1/2Results posted
- Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic MalignanciesCompletedNCT00795132Phase 2Results posted
- Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological CancerCompletedNCT00787761Phase 2Results posted
- Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other DiseaseTerminatedNCT00719849Phase 2Results posted
- Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantCompletedNCT00691015Phase 2Results posted
- Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00635024Phase 2Results posted
- Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT00629798Phase 2Results posted
- Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate MofetilTerminatedNCT00608517Not applicableResults posted
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AMLTerminatedNCT00568633Phase 3Results posted
- Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous LeukemiaCompletedNCT00553202Phase 2Results posted
- Study of Antithymocyte Globulin for Treatment of New-onset T1DMTerminatedNCT00515099Phase 2Results posted
- Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML PatientsTerminatedNCT00499889Phase 2Results posted
- Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCTTerminatedNCT00482053Phase 2Results posted
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's LymphomaTerminatedNCT00481832Phase 2Results posted
- Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAACompletedNCT00455312Phase 2/3Results posted
- Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseCompletedNCT00448201Phase 2Results posted
- Purine Analog-Based Conditioning in Patients With Severe Aplastic AnemiaCompletedNCT00427336Not applicableResults posted
- Donor Stem Cell Transplantation for Congenital ImmunodeficienciesCompletedNCT00426517Early Phase 1Results posted
- Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other DiseaseTerminatedNCT00392782Phase 2Results posted
- Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow TransplantCompletedNCT00343785Phase 2Results posted
- Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas TransplantationCompletedNCT00331162Phase 4Results posted
- Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood TransplantCompletedNCT00305682Phase 2Results posted
- Allogeneic Bone Marrow Transplantation Using Less Intensive TherapyTerminatedNCT00303719Phase 2Results posted
- Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerTerminatedNCT00281879Phase 2Results posted
- Three Immunosuppressive Treatment Regimens for Severe Aplastic AnemiaCompletedNCT00260689Phase 2Results posted
- Allogeneic Transplantation From Related Haploidentical DonorsCompletedNCT00185692Phase 2Results posted
- Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic MalignanciesCompletedNCT00185640Phase 2Results posted
- Stem Cell Transplantation for HurlerCompletedNCT00176917Phase 2Results posted
- Stem Cell Transplant for Inborn Errors of MetabolismCompletedNCT00176904Phase 2/3Results posted
- Stem Cell Transplant for Bone Marrow Failure SyndromesCompletedNCT00176878Phase 2/3Results posted
- Stem Cell Transplant for Immunologic or Histiocytic DisordersCompletedNCT00176865Phase 2Results posted
- NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/DisordersCompletedNCT00053989Phase 2Results posted
- Antithymocyte Globulin and Cyclosporine to Treat MyelodysplasiaCompletedNCT00005937Phase 2Results posted
- Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerCompletedNCT00003816Phase 2/3Results posted
- Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003270Phase 2Results posted
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)TerminatedNCT05600426Phase 3
- Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple SclerosisWithdrawnNCT05482542Not applicable
- TReatment for ImmUne Mediated PathopHysiologyActive, not recruitingNCT04862221Phase 2
- Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell TransplantationStatus unknownNCT04778618Phase 2
- ATG in HLA-matched Sibling HSCT as GVHD ProphylaxisStatus unknownNCT04203108Phase 4
- Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWithdrawnNCT03602898Phase 2
- T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic AnemiaActive, not recruitingNCT03531736Phase 1
- Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)Active, not recruitingNCT03477500Phase 3
- Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCTStatus unknownNCT03395860Phase 2
- A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCTStatus unknownNCT03190733Phase 4
- Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic AnemiaCompletedNCT02845596Not applicable
- Omental Islet TransplantCompletedNCT02821026Phase 1/2
- Allogeneic Stem Cell Transplantation for Children With CMLCompletedNCT02707393Phase 2/3
- Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)WithdrawnNCT02702960Phase 2
- Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCTCompletedNCT02677181Phase 4
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell TransplantationStatus unknownNCT02643589Not applicable
- Diabetes Islet Preservation Immune TreatmentWithdrawnNCT02586831Phase 1/2
- Minimal Islet Transplant at Diabetes OnsetCompletedNCT02505893Phase 2
- Allo-HSCT With Alternative Donor in Treatment of Hematologic MalignancyCompletedNCT02487069Not applicable
- Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic SyndromeCompletedNCT02462252Phase 2
- Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesCompletedNCT02122081Phase 1
- Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and AdolescentsStatus unknownNCT02014506Phase 1/2